canada clinical guidance

Prostate cancer referral

A Canadian clinical summary of prostate cancer referral, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Ontario is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.

Ontario source: bounded use

Prostate cancer pathway map supplies a Canadian implementation example for this summary. It must not be presented as the rule outside Ontario.
sources for this section:Ontario prostate pathway

Source-attributed clinical priorities

  • Assess urinary, bone and constitutional symptoms and perform a focused examination while identifying retention or spinal cord compression urgently.
  • Use shared decision-making for PSA testing, interpreting the result with age, prostate volume, infection, medicines and prior values.
  • Refer through the current provincial diagnostic pathway; PSA thresholds and wait-time targets are not one pan-Canadian rule.
  • Discuss PSA limitations and downstream biopsy consequences before testing an asymptomatic person.
sources for this section:Ontario prostate pathway

Practical assessment and management workflow

1
Assess lower urinary symptoms, hematuria, bone pain, family history, ancestry, life expectancy and previous PSA.
2
Perform examination and repeat or contextualize PSA when transient inflammation or instrumentation may distort it.
3
Use the provincial urology or rapid diagnostic pathway for concerning PSA, examination or symptoms.
4
Track referral and communicate results and safety-net progression while awaiting assessment.
sources for this section:Ontario prostate pathway

Safety, red flags and urgent escalation

  • Spinal pain with weakness or bladder or bowel dysfunction suggests metastatic cord compression.
  • Acute retention, renal failure or systemic infection requires urgent urologic care.
sources for this section:Ontario prostate pathway

Confirm the local pathway before acting

Ontario is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:Ontario prostate pathway

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Ontario prostate pathway

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Ontario Health (Cancer Care Ontario)Prostate cancer pathway mapaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.